LUNG

Pulmonx Corp

Add to Watchlist

Advanced Chart

1.550

-0.07(-4.321%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.670

Open

1.630

VWAP

1.59

Vol

797.71K

Mkt Cap

63.16M

Low

1.540

Amount

1.27M

EV/EBITDA(TTM)

Total Shares

38.82M

16.05M

EV/OCF(TTM)

P/S(TTM)

0.68

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

24.72M

+9.68%

-0.343

-4.86%

23.43M

-1.42%

-0.392

+18.69%

20.78M

+1.95%

-0.420

+16.67%

Estimates Revision

The market is revising Downward the revenue expectations for Pulmonx Corporation (LUNG) for FY2025, with the revenue forecasts being adjusted by -6.61% over the past three months. During the same period, the stock price has changed by -57.88%.

Revenue Estimates for FY2025

Revise Downward

-6.61%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.45%

In Past 3 Month

Stock Price

Go Down

-57.88%

In Past 3 Month

6 Analyst Rating

568.39% Upside

Wall Street analysts forecast LUNG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LUNG is 10.36 USD with a low forecast of 4.15 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

2 Hold

0 Sell

Moderate Buy

568.39% Upside

Current: 1.550

Low

4.15

Averages

10.36

High

16.00

568.39% Upside

Current: 1.550

Low

4.15

Averages

10.36

High

16.00

Citi

Neutral

downgrade

2025-05-22

Reason

Citi

Price Target

2025-05-22

downgrade

Neutral

Reason

Citi lowered the firm's price target on Pulmonx to $4.15 from $6.50 and keeps a Neutral rating on the shares. The firm updated models in medical technology following the Q1 reports. The good news is that underlying sector fundamentals appear intact, including volumes, pricing, and capex, the analyst tells investors in a research note.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$17

2025-03-11

Reason

D. Boral Capital

Jason Kolbert

Price Target

$17

2025-03-11

Maintains

Strong Buy

Reason

D. Boral Capital initiated coverage of Pulmonx with a Buy rating and $17 price target. The firm says Pulmonx is a commercial-stage medical technology company developing minimally invasive treatments for severe emphysema, a form of chronic obstructive pulmonary disease. With increasing physician adoption of the company's Zephyr Endobronchial Valve, strong reimbursement tailwinds, and international expansion opportunities, Pulmonx is well positioned for "significant growth," the analyst tells investors in a research note.

D. Boral Capital

Jason Kolbert

Strong Buy

Initiates

$17

2025-03-10

Reason

D. Boral Capital

Jason Kolbert

Price Target

$17

2025-03-10

Initiates

Strong Buy

Reason

Citigroup

Joanne Wuensch

Strong Buy

Hold

Downgrades

$17 → $7.5

2024-12-11

Reason

Citigroup

Joanne Wuensch

Price Target

$17 → $7.5

2024-12-11

Downgrades

Strong Buy

Hold

Reason

Citi downgraded Pulmonx to Neutral from Buy with a price target of $7.50, down from $17. The stock's 50% drop year-to-date "seems dislocated from the underlying momentum of the business yet it is unclear to us what will get the stock price moving in the right direction," the analyst tells investors in a research note. The firm does not see a path towards Pulmonx share price appreciation until revenue accelerates and profitability becomes more apparent.

Wells Fargo

Larry Biegelsen

Hold

Maintains

$10 → $8

2024-12-11

Reason

Wells Fargo

Larry Biegelsen

Price Target

$10 → $8

2024-12-11

Maintains

Hold

Reason

Stifel

Rick Wise

Strong Buy

Maintains

$17 → $16

2024-10-31

Reason

Stifel

Rick Wise

Price Target

$17 → $16

2024-10-31

Maintains

Strong Buy

Reason

Stifel lowered the firm's price target on Pulmonx to $16 from $17 and keeps a Buy rating on the shares. Pulmonx delivered solid outperformance in Q3 despite a seasonally slower operating environment in the quarter, aided by continued progress on all three of its commercial initiatives, the analyst tells investors in a research note. The firm views Pulmonx's the quarter and enhanced strategic initiatives positively for the company's rest-of-year and set up for 2025 and beyond.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Pulmonx Corp (LUNG.O) is -1.05, compared to its 5-year average forward P/E of -13.86. For a more detailed relative valuation and DCF analysis to assess Pulmonx Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-13.86

Current PE

-1.05

Overvalued PE

-1.31

Undervalued PE

-26.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-14.52

Current EV/EBITDA

-0.67

Overvalued EV/EBITDA

1.20

Undervalued EV/EBITDA

-30.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

12.66

Current PS

0.69

Overvalued PS

25.27

Undervalued PS

0.05